Q-omics provides the consensus-scored CA12 profile across patient tissues and cancer cell-line models. CA12 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, CA12 is differentially expressed in 12, with the highest sampling consensus in COAD. Additionally, CA12 protein abundance shows 21,728 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UVM, COAD, and GBM as cancer lineages where CA12 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CA12 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CA12 survival associations across molecular data types. CA12 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (2) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CA12 RNA expression–survival associations across cancer types. High CA12 expression shows unfavorable associations in UVM, UCS, PAAD, LUAD and HNSC, but favorable associations in BRCA. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for CA12 RNA expression.
This table summarizes CA12 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 7. The strongest signals are observed in COAD for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for CA12. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CA12 shows lower tumor expression in COAD and KIRP and higher tumor expression in LUSC, LIHC, HNSC and BRCA. The COAD box plot shows higher CA12 RNA expression in normal versus tumor tissue (log2 FC = −2.434, t-test p < 0.001).
This table shows molecular features associated with CA12 in patient tissues and cancer cell lines. In patient samples, CA12 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, CA12 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BONE.
